Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)

Amgen

Amgen clinical programs — 96 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
One Amgen Center Drive, Thousand Oaks, CA 91320, US
Founded
1980
Employees
40,212
Programs
96
Drugs
124
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Amgen projects

96 ClinicalTrials.gov programs sponsored by Amgen.

Amgen has 96 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

96 programs

Clinical programs

Page 2 of 2

  1. Rocatinlimab, Placebo for AMG 451

    Amgen

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  2. Tarlatamab

    Amgen

    Extensive-Stage Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. Tarlatamab

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  4. 20170104

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  5. 20180257

    Amgen

    Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,

    phase 2 small molecule active

    1 trial

  6. 20200491

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. 20210023

    Amgen

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  8. 20210210

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  9. 20220127

    Amgen

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. 20230302

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  11. 20240092

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  12. AMG 133, Placebo for AMG 133

    Amgen

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  13. AMG 193

    Amgen

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. AMG 732

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  15. Anvumetostat

    Amgen

    Advanced MTAP-null Solid Tumors

    phase 2 small molecule active

    1 trial

  16. Apremilast

    Amgen

    Palmoplantaris Pustulosis

    phase 2 small molecule completed

    1 trial

  17. Bemarituzumab

    Amgen

    Solid tumours

    phase 2 small molecule active

    1 trial

  18. Blinatumomab

    Amgen

    B Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  19. Blinatumomab SC2

    Amgen

    Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  20. Daxdilimab

    Amgen

    Lupus Nephritis

    phase 2 small molecule terminated

    1 trial

  21. Efavaleukin alfa

    Amgen

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  22. Placebo for AMG 133, AMG 133

    Amgen

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  23. Placebo for AMG 451, Rocatinlimab

    Amgen

    Moderate-to-severe Asthma

    phase 2 small molecule active

    1 trial

  24. Rocatinlimab

    Amgen

    Asthma

    phase 2 small molecule active

    1 trial

  25. SOTORASIB

    Amgen

    KRAS p.G12C Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  26. SOTORASIB

    Amgen

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  27. Tarlatamab

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  28. Uplizna 100 mg concentrate for solution for infusion

    Amgen

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  29. Uplizna 100 mg concentrate for solution for infusion

    Amgen

    Immunoglobulin G4 related Disease (IgG4-RD)

    phase 2 small molecule active

    1 trial

  30. 20160323

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

  31. 20180146

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  32. 20190135

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 other active

    1 trial

  33. 20200469

    Amgen

    Extensive Stage Small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  34. 20220028

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  35. 20230151

    Amgen

    Asthma

    phase 1 other active

    1 trial

  36. 20230167

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  37. 20230223

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  38. 20230237

    Amgen

    Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer

    phase 1 other active

    1 trial

  39. 20230298

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 other active

    1 trial

  40. 20240031

    Amgen

    KRAS Altered Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  41. 20240124

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 other active

    1 trial

  42. 20250004

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 other active

    1 trial

  43. A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

    Amgen

    Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer

    phase 1 other active

    1 trial

  44. Comparison between ABP 234 and Keytruda® (Pembrolizumab)

    Amgen

    Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  45. Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

  46. Tarlatamab

    Amgen

    Neuroendocrine Prostate Cancer

    phase 1 small molecule completed

    1 trial

  47. 20220159

    Amgen

    Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)

    approved small molecule active

    1 trial

  48. EVOLOCUMAB

    Amgen

    Dyslipidemia

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Amgen have?

96 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.